

S1 Table. Included randomized controlled trials characteristics

Study	Publication status	Baseline severity	N intervention group	N control group	Patients' characteristics	Intervention	Control	Standard of care (SOC) implemented	Additional interventions
Shouman et al; 2020	Peer-reviewed	Patients exposed to COVID-19 (ambulatory)	228	112	Mean age 38.72 ± 15.94, male 51.3%, HTN 9.5%, DM 7.6%, CKD 1%, asthma 3%, CHD 2.3%	Ivermectin 15 to 24 mg twice (second dose at day 3)	No intervention	NR	NR
Chowdhury et al; 2020	Pre-print	Patients with mild to moderate COVID-19 (ambulatory)	63	62	Mean age 33.9 ± 14.1, male 72.4%	Ivermectin plus doxycycline 200 µg/kg single dose + 100 mg BID for 10 days and	HCC 200 mg daily for 10 days + AZT 500 mg daily for 5 days	NR	NR
Podder et al; 2020	Peer-reviewed	Patients with mild to moderate COVID-19 (ambulatory)	32	30	Mean age 39.16 ± 12.07, male 71%	Ivermectin 200 µg/kg once + SOC	SOC	Antipyretics, cough suppressants, and capsule doxycycline (100 mg every 12 hours for seven days)	NR
Hashim et al; 2020	Pre-print	Patients with mild to severe COVID-19 (hospitalized)	70	70	Mean age 48.7 ± 8.6, male 52%	Ivermectin 200 µg/kg two or three doses + doxycycline 100 mg twice a day for 5 to 10 days + SOC	SOC	Vitamin C 1000 mg twice/ day and Zinc 75-125 mg/day and Vitamin D3 5000IU/day plus Dexamethasone 6 mg/day or methylprednisolone	Steroids 100%, azithromycin 100%,

								ne 40mg twice per day, if needed	
Mahmud et al; 2020	Peer-reviewed	Patients with mild to moderate COVID-19 (hospitalized)	200	200	Mean age 39.6 ± 13.2, male 58.8%, HTN 14%, DM 13%, asthma 5%, CKD 2%	Ivermectin plus doxycycline 12 mg once + 100 mg twice a day for 5 days + SOC	Placebo + SOC	Paracetamol, antihistamines, cough suppressants, vitamins, low molecular weight heparin, remdesivir injection	NR
Elgazzar et al (mild); ¹⁵¹ 2020	Pre-print	Patients with mild to moderate COVID-19 (hospitalized)	100	100	Mean age 55.2 ± 19.8, male 69.5%, HTN 11.5%, DM 14.5%, COPD %, asthma 5.5%, CHD 4%	Ivermectin 400 µg/kg once for 4 days + SOC and 100 patients assigned to	HQC 800 mg for one day and 400 mf for 4 days + SOC	Azithromycin 500mg OD for 6 days, Paracetamol 500mg PRN, vitamin C 1gm OD, Zinc 50 mg OD, Lactoferrin 100mg sachets BID , Acetylcystein 200mg t.d.s & prophylactic or therapeutic anticoagulation if D-dimer > 1000	NR
Elgazzar et al (severe); ¹⁵¹ 2020	Pre-print	Patients with severe COVID-19 (hospitalized)	100	100	Mean age 39.6 ± 13.2, male 58.8%, HTN 14%, DM 13%, asthma 5%, CKD 2%	Ivermectin 400 µg/kg once for 4 days + SOC	HQC 800 mg for one day and 400 mg for 9 days + SOC	Azithromycin 500mg OD for 6 days, Paracetamol 500mg PRN,	NR

								<p>vitamin C 1gm OD, Zinc 50 mg OD, Lactoferrin 100mg sachets BID , Acetylcystein 200mg sachets t.d.s , prophylactic or therapeutic anticoagulation if D-dimer > 1000 and systemic steroids</p>	
<p>Elgazzar et al (prophylaxis);¹ 51 2020</p>	Pre-print	<p>People exposed to SARS-COV-2 infection (ambulatory)</p>	100	100	<p>Mean age: 57.2, male 73.5%, DM 17%, HTN 14.5%, CHD 2%, asthma 4.5%</p>	<p>Ivermectin 400 µgm/kg twice (second dose after one week) + SOC</p>	SOC	<p>Personal protective measures (PPM): hand hygiene, social distance measures, avoiding touching the eyes, nose, and, face masks, gloves, respiratory etiquette and self- isolation</p>	NR
<p>Krolewiecki et al;¹⁵² 2020</p>	Peer- reviewed	<p>Patients with mild to moderate COVID-19 (hospitalized)</p>	30	15	<p>Mean age 40.9 ± 12.5, male 56%, HTN 13.3%, DM 15.5%, COPD and asthma 11.1%, obesity 38%</p>	<p>Ivermectin 0.6 mg/kg for 5 days + SOC</p>	SOC	NR	NR

Niaee et al; ¹⁵³ 2020	Pre-print	Patients with mild to severe COVID-19 (hospitalized)	120	60	Median age 56 ± 20, male 50%	Ivermectin 200 microg/kg once + SOC or Ivermectin 200 microg/kg daily for 3 days + SOC or Ivermectin 400 microg/kg once + SOC or Ivermectin 400 microg/kg once + 200 microg/kg daily for 2 days + SOC	SOC or placebo + SOC	Hydroxychloroquine 200mg/kg twice per day	NR
Ahmed et al; ¹⁵⁴ 2020	Peer-reviewed	Patients with mild to moderate COVID-19 (hospitalized patients)	24	24	Mean age 42, male 46%,	Ivermectin 12 mg a day for 5 days or ivermectin 12 mg a day for 5 days + doxycycline 100 mg and	placebo	NR	NR
Chaccour et al; 2020	Peer-reviewed	Patients with mild COVID-19 (early within 3 days of onset, ambulatory)	12	12	Median age 26, male 50%,	Ivermectin 400 microg/kg	placebo	NR	NR
Chachar et al; ¹⁵⁶ 2020	Peer-reviewed	Patients with mild COVID-19 (ambulatory)	25	25	Mean age 41.8±15.7, male 62%, HTN 26%, DM 40%, obesity 12%, CHD 8%	Ivermectin 36mg once + SOC	SOC	NR	NR
Babalola et al; ¹⁵⁷ 2020	Peer-reviewed	Patients with mild to	21	20	Mean age 44.1 ± 14.7, male 69.4%, HTN 14.5%,	Ivermectin 12 mg a week + SOC, or	lopinavir-ritonavir + SOC	Zinc 62%	Steroids 3.2%,

		severe COVID-19 (ambulatory and hospitalized)			DM 3.2%	ivermectin 24 mg a week for 2 weeks + SOC			
Kirti et al; 2020	Pre-print	Patients with mild to moderate COVID-19 (hospitalized)	55	57	Mean age 52.5 ± 14.7, male 72.3%, HTN 34.8%, DM 35.7%, COPD 0.9%, asthma 0.9%, CHD 8.9%, CKD 2.7%, cerebrovascular disease 0%, cancer 5.4%	Ivermectin 24mg divided in two doses + SOC	Placebo + SOC	Steroids 100%, HCQ 100%	remdesivir 20.5%, tocilizumab 6.3%, convalescent plasma 13.4%
Chahla et al; 2020	Pre-print	People exposed to SARS-COV-2 infection (ambulatory)	117	117	Median age 38 ± 12.5, male 42.7%, HTN 9%, DM 7.3%, CKD 2.1%, obesity 11.9%	Ivermectin + iota-carrageenan 12mg a week + 6 sprays a day for 4 weeks + SOC and	SOC	Standard biosecurity care and personal protective equipment (PPE)	NR
Mohan et al; ¹⁵⁹ 2020	Pre-print	Patients with mild to moderate COVID-19 (hospitalized)	100	52	Mean age 35.3 ± 10.4, male 88.8%, HTN 11.2%, DM 8.8%, CHD 0.8%	Ivermectin 12 mg (equivalent to 200 µg/kg) elixir + SOC or Ivermectin 24 mg (equivalent to 400 µg/kg) + SOC	Placebo + SOC	NR	Steroids 14.4%, remdesivir 1.6%, hydroxychloroquine 4%, azithromycin 11.2%
Samaha et al; ¹⁵⁹ 2020	Peer-reviewed	Patients with asymptomatic SARS-COV-2 infection (ambulatory)	50	50	Mean age: 31.78 ± 7.85, male 50%, HTN 8%, DM 6%	Ivermectin 0.2 mg/kg once + SOC	SOC	Zinc (30–50 mg/day) and Vitamin C (500 mg BID, twice daily) supplements	NR

Bukhari et al; ¹⁶⁰ 2020	Pre-print	Patients with mild to moderate COVID-19 (hospitalized)	50	50	Mean age: 40.6, males 73%, HTN 14%, DM 11.6%, CHD 5.8%	Ivermectin 12 mg once + SOC	SOC	vitamin C 500 mg once daily, vitamin D3 200,000 IU once weekly, Paracetamol 500 mg if necessary.	NR
Okumus et al; ¹⁶¹ 2021	Peer-reviewed	Patients with severe COVID-19 (hospitalized)	36	30	Mean age 62 ± 12, male 60.6%, HTN 45%, DM 31.6%, COPD 15%, CHD 21.6%, cancer 1.6%	Ivermectin 0.2 mg/kg for 5 day + SOC	SOC	Hydroxychloroquine (2x400mg loading dose followed by 2x200mg for 5 days), favipiravir (2x1600mg loading dose followed by 2x600mg maintenance dose, po, total 5 days)	NR
Beltran-Gonzalez et al; ¹²⁶ 2021	Pre-print	Patients with moderate to severe COVID-19 (hospitalized)	36	37	Mean age 54 ± 23.5, male 46.8%, HTN 19.1%, DM 9.6%, COPD 1%, CHD 7.4%, cerebrovascular disease 5.3%	Ivermectin 12-18 mg once	Placebo	dexamethasone, 6 mg IV every 24 hours, unfractionated heparin	Steroids 9.6%, lopinavir-ritonavir 44.7%
Lopez-Medina et al; ¹⁶² 2021	Peer-reviewed	Patients with mild COVID-19 (ambulatory)	238	238	Median age 37 ± 19, male 42%, HTN 13.4%, DM 5.5%, COPD 3%, CHD 1.7%, cancer %, obesity 18.9%	Ivermectin 300 µg/kg a day for 5 days	Placebo	NR	Steroids 4.5%
Bermejo	Peer-	Patients with	53	54	Mean age 53.4 ± 15.6,	Ivermectin 42mg	CQ 900 mg for 1 day,	Azithromycin (500	Steroids 98%

Galan et al; ¹²⁸ 2021	reviewed	severe to critical COVID-19 (hospitalized)			male 58.2%, HTN 43.4%, DM 28.1%, COPD 5.3%, CKD 2.5%, cancer 3%, obesity 37.5%		and 450 mg for 4 days or HCQ 800 mg for 1 day and 400 mg for 4 days	mg 1× for 5 days) and ceftriaxone (1 g 2× for 7 days). Oseltamivir (75 mg 2× for 5 days) Proportions NR Steroids 98%	
Pott-Junior et al; ¹⁶³ 2021	Peer-reviewed	Patients with mild to severe COVID-19 (hospitalized)	28	7	Mean age 49.4 ± 14.6, male 45.2%	Ivermectin 100 + SOC or ivermectin 200 mc/kg + SOC or ivermectin 400 mcg/kg + SOC	SOC	NR.	Steroids 32.3%
Kishoria et al; ¹⁶⁴ 2021	Peer-reviewed	Patients with asymptomatic to mild COVID-19 (ambulatory)	19	16	Mean age 38 ±, male 66%	Ivermectin 12mg single dose + SOC	SOC	Hydroxychloroquine 400 mg twice a day, Paracetamol 500mg as required, Vitamin C 1 tab twice a day; for five days	NR
Seet et al; ¹²⁹ ; 2021	Peer-reviewed	People exposed to SARS-COV-2 infection. (ambulatory)	709	633	Mean age 33, male 100%, hypertension 0.8%, diabetes 0.3%	Ivermectin 12mg once	vitamin C	NR	NR
Shahbaznejad et al; 2020	Peer-reviewed	Patients with moderate to critical COVID-19	35	38	Mean age 46.4 ± 22.5, male 52.2%	Ivermectin 0.2 mg/kg once + SOC	SOC	Chloroquine 75.4%, lopinavir-ritonavir 79.7%, antibiotics 89.8%	NR

		(hospitalized)							
Abd-Elsalam S et al.; 2021	Peer-reviewed	Patients with mild to moderate COVID-19 infection (hospitalized)	82	82	Mean age 40.9 ± 16.5, male 50%, HTN 20%, DM 16%	Ivermectin 12 mg a day for 3 days + SOC	SOC	Paracetamol, oxygen, fluids (according to the condition of the patient), empiric antibiotic, oseltamivir if needed (75 mg/12 h for 5 days)	NR
Biber et al; 2021	Pre-print	Patients with mild recent onset COVID19 (ambulatory)	47	42	Mean age 35 ± 19, male 78.4%	Ivermectin 48 to 55 mg administered for three days + SOC	SOC	NR	NR
Faisal et al; 2021	Peer-reviewed	Patients with mild COVID-19 (ambulatory)	50	50	Mean age 46 ± 3, male 80%	Ivermectin 12 mg a day for 5 days + SOC	SOC	Paracetamol (500mg if needed), Vit C (500mg once a day for 15 days), zinc (20mg twice a day for 15 days) and Vit D (injection PO 200,000units once) supplements.	NR
Vallejos et al; 2021	Peer-	Patients with mild	250	251	Mean age 42.5 ± 15.5, male 52.7%, hypertension	Ivermectin 24 to 36mg (according to baseline	SOC	NR	NR

	reviewed	COVID-19 (ambulatory)			23.8%, diabetes 9.6%, COPD 2.8%, asthma 7.2%, CHD 1.8%, cancer 1.2%	bodyweight) divided in 2 doses			
--	----------	--------------------------	--	--	---	-----------------------------------	--	--	--

SOC: standard of care; NR: not registered; HTN: arterial blood hypertension; DM: diabetes mellitus; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; CHD: coronary heart disease; CQ: chloroquine; HCQ: hydroxychloroquine.